The purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children 6-12 years of age with Down syndrome (DS) after 8 weeks of treatment.
Hyperactivity in Children with Down Syndrome, Impulsivity in Children with Down Syndrome
The purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children 6-12 years of age with Down syndrome (DS) after 8 weeks of treatment.
Guanfacine for Hyperactivity in Children with Down Syndrome (HYPEbeGONE_DS)
-
Phoenix Childrens Hospital, Phoenix, Arizona, United States, 85016
Yale University School of Medicine, New Haven, Connecticut, United States, 06250
Emory University, Atlanta, Georgia, United States, 30322
Ann and Robert H. Lurie Hospital of Chicago, Chicago, Illinois, United States, 60611
University of Iowa, Iowa City, Iowa, United States, 52242
Kennedy Krieger Institute, Baltimore, Maryland, United States, 21205
Boston Children's Hospital, Boston, Massachusetts, United States, 02115
Massachusetts General Hospital, Lexington, Massachusetts, United States, 02421
Atrium Health-Wake Forest School of Medicine, Charlotte, North Carolina, United States, 28204
Duke University Hospital, Durham, North Carolina, United States, 27705
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
6 Years to 12 Years
ALL
Yes
Rachel G. Greenberg, MD, MB, MHS,
Rachel Greenberg, PRINCIPAL_INVESTIGATOR, DCRI
2026-02